Wolff Wiese Magana LLC lifted its position in shares of Eli Lilly and Company (NYSE:LLY – Get Rating) by 16.1% during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 569 shares of the company’s stock after purchasing an additional 79 shares during the period. Wolff Wiese Magana LLC’s holdings in Eli Lilly and were worth $185,000 as of its most recent SEC filing.
Other institutional investors have also recently added to or reduced their stakes in the company. Cordant Inc. bought a new stake in Eli Lilly and during the first quarter valued at $25,000. HWG Holdings LP bought a new stake in Eli Lilly and during the fourth quarter valued at $28,000. Icapital Wealth LLC bought a new stake in Eli Lilly and during the first quarter valued at $28,000. Selective Wealth Management Inc. bought a new stake in Eli Lilly and during the first quarter valued at $33,000. Finally, Oliver Lagore Vanvalin Investment Group bought a new position in shares of Eli Lilly and during the first quarter worth about $33,000. 82.45% of the stock is owned by institutional investors and hedge funds.
Analysts Set New Price Targets
Several equities analysts have recently commented on the stock. JPMorgan Chase & Co. upped their price target on shares of Eli Lilly and from $340.00 to $355.00 in a research report on Wednesday, June 1st. Morgan Stanley increased their target price on shares of Eli Lilly and from $395.00 to $412.00 and gave the company an “overweight” rating in a research report on Wednesday, September 7th. Citigroup increased their target price on shares of Eli Lilly and from $285.00 to $370.00 in a research report on Thursday, August 25th. UBS Group upgraded shares of Eli Lilly and from a “neutral” rating to a “buy” rating and increased their target price for the company from $335.00 to $363.00 in a research report on Thursday. Finally, StockNews.com upgraded shares of Eli Lilly and from a “buy” rating to a “strong-buy” rating in a research report on Wednesday, September 14th. Three investment analysts have rated the stock with a hold rating, thirteen have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, Eli Lilly and currently has a consensus rating of “Moderate Buy” and an average price target of $332.19.
Eli Lilly and Stock Up 0.2 %
Eli Lilly and (NYSE:LLY – Get Rating) last released its quarterly earnings data on Thursday, August 4th. The company reported $1.25 EPS for the quarter, missing analysts’ consensus estimates of $1.86 by ($0.61). Eli Lilly and had a return on equity of 85.58% and a net margin of 19.58%. The firm had revenue of $6.49 billion during the quarter, compared to analyst estimates of $6.85 billion. During the same quarter in the prior year, the company posted $1.87 EPS. The company’s quarterly revenue was down 3.7% on a year-over-year basis. As a group, equities research analysts expect that Eli Lilly and Company will post 7.97 EPS for the current year.
Eli Lilly and Dividend Announcement
The company also recently disclosed a quarterly dividend, which was paid on Friday, September 9th. Investors of record on Monday, August 15th were issued a $0.98 dividend. The ex-dividend date was Friday, August 12th. This represents a $3.92 dividend on an annualized basis and a yield of 1.26%. Eli Lilly and’s dividend payout ratio is currently 62.52%.
Insider Buying and Selling
In other Eli Lilly and news, SVP Alonzo Weems sold 656 shares of the stock in a transaction that occurred on Wednesday, August 10th. The stock was sold at an average price of $304.50, for a total transaction of $199,752.00. Following the transaction, the senior vice president now owns 8,136 shares in the company, valued at $2,477,412. The sale was disclosed in a filing with the SEC, which is available at the SEC website. In other news, major shareholder Lilly Endowment Inc sold 89,458 shares of the firm’s stock in a transaction on Thursday, July 28th. The shares were sold at an average price of $332.85, for a total value of $29,776,095.30. Following the sale, the insider now owns 103,875,441 shares in the company, valued at $34,574,940,536.85. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, SVP Alonzo Weems sold 656 shares of the firm’s stock in a transaction on Wednesday, August 10th. The stock was sold at an average price of $304.50, for a total transaction of $199,752.00. Following the completion of the sale, the senior vice president now owns 8,136 shares in the company, valued at approximately $2,477,412. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 328,125 shares of company stock worth $108,581,151. Insiders own 0.12% of the company’s stock.
Eli Lilly and Profile
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes.
- Get a free copy of the StockNews.com research report on Eli Lilly and (LLY)
- Why Does Tesla Stock Remain Resilient?
- Will Crowdstrike Get A Boost From Increased EPS Guidance?
- 2 Semiconductor Stocks To Watch For Reversals
- Are Layoffs At A Small-Cap Tech A Bellwether For Housing Stocks?
- Is Costco’s Post-Earnings Price Weakness A Good Time To Buy?
Receive News & Ratings for Eli Lilly and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and and related companies with MarketBeat.com's FREE daily email newsletter.